Dong-A, Asahi Kasei join forces over Flivas

Published: 2009-04-17 06:56:00

Updated: 2009-04-17 06:56:00

Dong-A Pharmaceutical announced on April 15 that it has entered into an exclusive license agreement Asahi Kasei Pharma in Japan, granting Dong-A to develop and sales of naftopidil, an agent for the treatment of benign prostatic hyperplasia (BPH) marketed as Flivas in Korea.

According to Dong-A, Flivas is expected to be commercialized in 2011. The domestic BPH market size is estimated to be 1...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.